March 7, 2024 06:48 AM ESTUpdated 05:38 PM
R&D

GSK de­clares sec­ond PhI­II win for Blenrep com­bo in bid to re­vive drug

Amber Tong

Blenrep, GSK’s BC­MA-tar­get­ing an­ti­body-drug con­ju­gate, has once again beat the stan­dard of care when giv­en as part of a com­bi­na­tion to pa­tients with re­lapsed/re­frac­to­ry mul­ti­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

A service from the Financial Times